Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy

Diabetes is associated with several diabetic-related abnormalities which increase the risk of onset or worsening of heart failure. Recent studies showed that the majority of diabetic patients present with heart failure with preserved ejection fraction (HFpEF), and the prevalence of HFpEF in diabetic...

Full description

Saved in:
Bibliographic Details
Main Authors: Jakub Benko, Matej Samoš, Tomáš Bolek, Dana Prídavková, Jakub Jurica, Martin Jozef Péč, Peter Galajda, Marián Mokáň
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Journal of Diabetes Research
Online Access:http://dx.doi.org/10.1155/2022/3366109
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850226523979644928
author Jakub Benko
Matej Samoš
Tomáš Bolek
Dana Prídavková
Jakub Jurica
Martin Jozef Péč
Peter Galajda
Marián Mokáň
author_facet Jakub Benko
Matej Samoš
Tomáš Bolek
Dana Prídavková
Jakub Jurica
Martin Jozef Péč
Peter Galajda
Marián Mokáň
author_sort Jakub Benko
collection DOAJ
description Diabetes is associated with several diabetic-related abnormalities which increase the risk of onset or worsening of heart failure. Recent studies showed that the majority of diabetic patients present with heart failure with preserved ejection fraction (HFpEF), and the prevalence of HFpEF in diabetics is alarming. Moreover, outcomes in HFpEF are poor and could be compared to those of heart failure with reduced ejection fraction (HFrEF), with 1-year mortality ranging between 10 and 30%. In contrast to HFrEF, there is very limited evidence for pharmacologic therapy in symptomatic patients with preserved ejection fraction, and therefore, the optimal selection of treatment for diabetic HFpEF remains challenging. This narrative review article summarizes the currently available data on the pharmacological treatment of HFpEF in patients with diabetes.
format Article
id doaj-art-5573367a6d6f4ffd813b90803aaa1e2b
institution OA Journals
issn 2314-6753
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Journal of Diabetes Research
spelling doaj-art-5573367a6d6f4ffd813b90803aaa1e2b2025-08-20T02:05:03ZengWileyJournal of Diabetes Research2314-67532022-01-01202210.1155/2022/3366109Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current PharmacotherapyJakub Benko0Matej Samoš1Tomáš Bolek2Dana Prídavková3Jakub Jurica4Martin Jozef Péč5Peter Galajda6Marián Mokáň7Department of Internal Medicine IDepartment of Internal Medicine IDepartment of Internal Medicine IDepartment of Internal Medicine IDepartment of Internal Medicine IDepartment of Internal Medicine IDepartment of Internal Medicine IDepartment of Internal Medicine IDiabetes is associated with several diabetic-related abnormalities which increase the risk of onset or worsening of heart failure. Recent studies showed that the majority of diabetic patients present with heart failure with preserved ejection fraction (HFpEF), and the prevalence of HFpEF in diabetics is alarming. Moreover, outcomes in HFpEF are poor and could be compared to those of heart failure with reduced ejection fraction (HFrEF), with 1-year mortality ranging between 10 and 30%. In contrast to HFrEF, there is very limited evidence for pharmacologic therapy in symptomatic patients with preserved ejection fraction, and therefore, the optimal selection of treatment for diabetic HFpEF remains challenging. This narrative review article summarizes the currently available data on the pharmacological treatment of HFpEF in patients with diabetes.http://dx.doi.org/10.1155/2022/3366109
spellingShingle Jakub Benko
Matej Samoš
Tomáš Bolek
Dana Prídavková
Jakub Jurica
Martin Jozef Péč
Peter Galajda
Marián Mokáň
Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy
Journal of Diabetes Research
title Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy
title_full Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy
title_fullStr Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy
title_full_unstemmed Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy
title_short Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy
title_sort diabetic heart failure with preserved left ventricular ejection fraction review of current pharmacotherapy
url http://dx.doi.org/10.1155/2022/3366109
work_keys_str_mv AT jakubbenko diabeticheartfailurewithpreservedleftventricularejectionfractionreviewofcurrentpharmacotherapy
AT matejsamos diabeticheartfailurewithpreservedleftventricularejectionfractionreviewofcurrentpharmacotherapy
AT tomasbolek diabeticheartfailurewithpreservedleftventricularejectionfractionreviewofcurrentpharmacotherapy
AT danapridavkova diabeticheartfailurewithpreservedleftventricularejectionfractionreviewofcurrentpharmacotherapy
AT jakubjurica diabeticheartfailurewithpreservedleftventricularejectionfractionreviewofcurrentpharmacotherapy
AT martinjozefpec diabeticheartfailurewithpreservedleftventricularejectionfractionreviewofcurrentpharmacotherapy
AT petergalajda diabeticheartfailurewithpreservedleftventricularejectionfractionreviewofcurrentpharmacotherapy
AT marianmokan diabeticheartfailurewithpreservedleftventricularejectionfractionreviewofcurrentpharmacotherapy